CF Industries: The Market Is Paying For the War, Not the Molecule

CF Industries: The Market Is Paying For the War, Not the Molecule

CF Industries printed roughly $3 billion of adjusted EBITDA through nine months of 2026 — already above the company's own mid-cycle EBITDA estimate of $2.9B for a full year — and promptly watched its stock sag about 15% from the early-September peak of $139.27. That is the tension worth writing about. The earnings are extraordinary; the tape is suspicious; management is annoyed.

we believe the market continues to ascribe too much of our earnings and free cash flow performance to short-term geopolitical factors. Structural advantages Chris discussed, combined with the global nitrogen supply-demand dynamics Bert outlined, underpin our confidence in CF Industries' mid-cycle earnings power. We do not believe our earnings power is fully reflected in our valuation

What Actually Changed: The Clock, Not the Numbers

The genuinely new information on this call was a timetable compression, not a volume or price upgrade. Asked about the 35%+ of European ammonia capacity sitting curtailed, Chris Bohn did not repeat the long-standing 2030 closure script — he pulled it forward: “we believe it is going to accelerate from what we thought was a 2030 timeframe with some of those European shutdowns to occur, whether it be 12 months or 18 months sooner than that” — Chris Bohn, President and CEO · 2026-11-05. The logic is mechanical and convincing: every quarter a plant idles, the restart capital and the fixed-overhead absorption make a future restart less likely, not more. That is a one-way ratchet.

The second new item was a surprise from the supply side of the supply side. China, having already authorized roughly nine million tons of urea exports versus under five last year, moved to put quotas on ammonium sulfate exports — the cheap urea substitute that has been quietly loosening the balance. Bert Frost's reaction was blunt: “That was a surprise.” — Bert Frost, Executive Vice President and Chief Commercial Officer · 2026-11-05 He tied it to sulfur costs and competing sulfuric acid demand. Add in the roughly nine million tons of urea supply lost since Middle East hostilities began in late February, and the curtailment math gets uncomfortable for anyone short the molecule.

The third item is the one management would prefer you skim. Yazoo City slipped again. On the February call, the ammonium nitrate rebuild was framed as a late-Q4 2026 restart. By August it had moved to the first half of 2027 on electrical gear lead times. On this call, Bohn confirmed it is a ramp beginning in 1H27, with AN production only in the second half: “towards the end of the first half of next year, that we will be starting up components of that plant” — Chris Bohn, President and CEO · 2026-11-05. Andrew Scribner's framing — that capital spend and insurance recoveries will "largely offset" over the longer term — is the right accounting answer and the wrong reassurance. A plant that has been down roughly a year and a half keeps bleeding fixed-cost absorption into cost of sales; that was already visible in Q2, where he attributed part of the fixed-cost gap to Yazoo, and it is why controllable non-gas costs are running about $200 million above year-ago levels.

The Cash Machine, Verified

Here the numbers back the narrative rather than complicating it. Trailing-twelve-month operating cash flow was roughly $3.1 billion against free cash flow of roughly $2 billion, and CF has consistently converted about 60% of EBITDA to free cash — “the highest rate in the materials sector and well above other fertilizer companies” — Chris Bohn, President and CEO · 2026-11-05. The reported quarter shows the same engine at work: free cash flow margin of 26.9%, and gross margin of 51.5%, up 11.6 points year over year. Revenue of $2.2 billion was up 18%.

The balance sheet is the quiet advantage. Effective net cash of $1.7 billion — a company that was levered at roughly $4.7 billion net debt a decade ago now funds a $3.7 billion Blue Point ammonia project out of cash flow while buying back stock. Capital expenditure for 2026 is guided to about $1.3 billion consolidated, with CF's share around $950 million. Over the last twelve months CF returned $1.3 billion, repurchasing about 6% of shares outstanding; over three years, 22%.

And the multiple: price to net income of 6.6x. That is the whole argument in one number.

The Demand Side Is Doing Its Job — With Caveats

The constructive case needs demand, and CF got it. UAN shipments hit nearly two million tons, the largest quarterly volume this decade, driven by a late-summer UAN program that rolled up over two million tons of orders at prices starting in the high $280s and averaging $322 for Q3. Fall ammonia participation is tracking among the highest in ten years. Frost's read-through is 95–96 million corn acres for 2027, potentially higher, with a $4.75 harvest floor from the Crop Revenue Guarantee program supporting farmer psychology against soft corn prices.

The soft spots are real and were flagged honestly. Brazil urea imports are expected down about a million tons versus 2025 on credit constraints, with total NPK demand down seven to nine million tons — and the Mato Grosso super El Niño risk is an explicit overhang. Urea has lagged ammonia and UAN: NOLA is around $430 a short ton for Q4 against $360–$380 a year ago, only about 10% higher despite everything that has broken. Frost's explanation — “when you combine demand deferral globally with prompt demand in Europe, I think that's why we're not escalating in price to the level that probably you would expect” — Bert Frost, Executive Vice President and Chief Commercial Officer · 2026-11-05 — is coherent, but it is also the third or fourth consecutive quarter in which "the catch-up is coming" has been the answer. That deferral thesis was made explicitly back in August: “we do believe that is going to catch up” — Bert A. Frost, Executive Vice President and Chief Commercial Officer · 2026-08-06. Some of it has; not all.

The Disconnect Is Now a Multi-Year Theme

What makes CF unusual is that the structural advantages argument — low risk North American gas, unmatched terminal and pipeline distribution, industry-leading conversion — has been management's refrain for many quarters running, and the discount has persisted through all of them. Bohn said in August: “I think people are still trading 10 years ago on CF” — Christopher D. Bohn, President and CEO · 2026-08-06. Two quarters later the stock is lower than it was then, the buyback authorization is still substantial, and the message has not changed one word.

The honest reading: this is a company whose earnings power has structurally improved — European capacity is exiting, newbuild lead times have stretched 12–18 months for anyone starting today, and Blue Point's long-lead pre-ordering now looks prescient — while its multiple still prices it as a cyclical fertilizer name hostage to headlines about the Strait of Hormuz. Frost's supply-recovery estimate is the crux of that gap: “If hostilities were to end tomorrow, I would think it would take months to get back to what is a quote-unquote "normal volume"” — Bert Frost, Executive Vice President and Chief Commercial Officer · 2026-11-05 — four to six months, in his words, before Gulf flows normalize.

So the trade is not "nitrogen is tight." The market knows. The trade is whether a 6.6x earnings multiple on a net-cash balance sheet, a $2.9 billion mid-cycle floor rising to $3.3 billion by 2030, and a management buying 6% of the float annually is a mispricing or a warning. The new evidence this quarter — accelerated European closures, Chinese ammonium sulfate quotas, a slipping Yazoo restart — cuts both ways: it lengthens the tailwind and it lengthens the drag.